



ERIC HOLCOMB, GOVERNOR  
STATE OF INDIANA

*Office of Medicaid Policy and Planning*  
MS 07, 402 W. WASHINGTON STREET, ROOM W382  
INDIANAPOLIS, IN 46204-2739

## MEETING AGENDA AND PUBLIC NOTIFICATION

Therapeutics Committee

February 2, 2024

9:00 A.M. EST

### Hybrid Meeting

Indiana State Government Center South

Conference Center Room C

Virtual Meeting Information Below

1. Call to Order-Chair
2. Opening Comments-OMPP
3. Approval of Memoranda, Meeting of November 3, 2023
4. Election of Officers - CY2024
5. Preferred Drug List: Therapeutic Class Re-Review
  - a) Respiratory
    - i. Antihistamine-Decongestant Combinations/2<sup>nd</sup> Generation Antihistamines
    - ii. Antiviral Monoclonal Antibodies
    - iii. Beta Adrenergics and Corticosteroids
    - iv. Beta Agonists
    - v. Bronchodilator Agents - Beta Adrenergic and Anticholinergic Combinations
    - vi. Leukotriene Receptor Antagonists
    - vii. Nasal Antihistamines/Nasal Anti-Inflammatory Steroids



- viii. Oral Inhaled Glucocorticoids
- ix. Pulmonary Antihypertensives
- x. Respiratory and Allergy Biologics
- b) Anti-Infectives
  - i. Antivirals - Anti-Herpetic Agents
  - ii. Antivirals - Influenza Agents
  - iii. Cephalosporins - 3<sup>rd</sup> Generation
  - iv. Fluoroquinolones
  - v. Hepatitis C Agents
  - vi. Macrolides
  - vii. Ophthalmic Antibiotics
  - viii. Ophthalmic Antibiotics/Corticosteroid Combinations
  - ix. Otic Antibiotics
  - x. Systemic Antifungals
  - xi. Topical Antifungals
  - xii. Topical Antivirals
  - xiii. Topical Antivirals and Anti-Inflammatory Steroid Combinations
  - xiv. Vaginal Antimicrobials
- c) Cardiovascular
  - i. Angiotensin-Converting Enzyme (ACE) Inhibitors
  - ii. ACE Inhibitor Combinations
  - iii. Angiotensin II Receptor Antagonists (ARBs)
  - iv. ARB Combinations
  - v. Beta Adrenergic Blockers
  - vi. Beta Adrenergic Blockers with Diuretics
  - vii. Calcium Channel Blockers (CCBs)
  - viii. Miscellaneous Cardiac Agents
- d) Lipotropics
  - i. Bile Acid Sequestrants
  - ii. Fibrin Acid Derivatives
  - iii. HMG-CoA Reductase Inhibitors

- iv. Lipotropics
  - e) Antimigraine Agents
  - f) Electrolyte Depleters
  - g) Multiple Sclerosis Agents
  - h) Targeted Immunomodulators
- 6. New Business
- 7. Public Comment
- 8. Other Business
- 9. Adjourn

---

## Microsoft Teams meeting

**Join on your computer, mobile app or room device**

[Click here to join the meeting](#)

Meeting ID: 296 907 630 090

Passcode: zVLAMQ

[Download Teams](#) | [Join on the web](#)

**Join with a video conferencing device**

[425899727@t.plcm.vc](mailto:425899727@t.plcm.vc)

Video Conference ID: 119 332 109 01

[Alternate VTC instructions](#)

**Or call in (audio only)**

[+1 952-222-7450,678374932#](tel:+1952227450678374932) United States, Bloomington

Phone Conference ID: 678 374 932#

[Find a local number](#) | [Reset PIN](#)

[Learn More](#) | [Help](#) | [Meeting options](#)